Alex Zhavoronkov, PhD (aka Aleksandrs Zavoronkovs) ✓
@biogerontology · joined 12 Feb 2010
My posts are strictly personal, not reflective of positions or policies of Insilico Medicine, which disclaims any responsibility for my individual statements.
39 417Followers
1 798Following
15 372Posts total
13.4KViews on collected posts
Latest posts
Looking for new posts…
We published specialist AI models that outperform dedicated computational chemistry tools across 70+ benchmarks. ADMET, retrosynthesis, GPCR panels, kinase panels. General-purpose LLMs, fine-tuned right, now beat specialized scientific tools.
1.2K views · 13 likes
· 1 reposts · 4 replies
Open on X →
Semaglutide extended lifespan in aged female mice — Feng, Barthez et al., Danica Chen lab, in Nature today.
3 months of GLP-1R agonism at 20 months old improved function, dialed down hallmarks of aging, hit conserved nutrient-sensing pathways. Head-to-head vs calorie https://t.c
2.4K views · 54 likes
· 23 reposts · 9 replies
Open on X →
To explain a black-box medical image classifier, most counterfactual methods train a second black box (GAN/diffusion). This King's College London paper drops the generator, building counterfactuals from the classifier's causal evidence. 85% on brain MRI.
https://t.co/oHljtEL6nQ
1.2K views · 18 likes
· 5 reposts · 0 replies
Open on X →
Roughly 10% to 20% of all recognized human diseases are directly caused by the total presence, absence, or structural alteration of a single, specific protein.
However, if you broaden the scope to include conditions where a specific protein plays a primary causal driver (even if
64 views · 1 likes
· 0 reposts · 1 replies
Open on X →
@biogerontology Uhh it's an SGLT2 inhibitor. We already know it treats heart failure. Positive phase 3 trials, in guidelines, the whole deal. Chronic kidney disease and diabetes too. They don't cause much weight loss though. Hope the pandaomics finds something.
118 views · 2 likes
· 0 reposts · 1 replies
Open on X →
@biogerontology Depends on the biology. Repurposing works when the hits are mechanistically plausible, not just retrospective correlations in omics data. Good test case.
25 views · 0 likes
· 0 reposts · 0 replies
Open on X →
Most drug development goes: pick disease -> find molecule -> spend decade learning you were wrong.
THPharm reversed it. THP-001 is already in global Phase 3. Now they're feeding its full biological fingerprint into PandaOmics to ask: what else does this drug treat?
16 datasets,
4.2K views · 94 likes
· 14 reposts · 6 replies
Open on X →
Panelists: Jeffrey Siegel (Director, Office of Drug Evaluation Sciences, CDER/FDA), Justin Penzenstadler (Associate Director, OCHEN/OND/CDER/FDA), Lowell M. Zeta (Acting Chief of Staff, Office of the Commissioner, FDA).
Full program: https://t.co/J8vdGriSGu
664 views · 0 likes
· 0 reposts · 1 replies
Open on X →
ARDD 2026 comes to the US for the first time. October 1, 10:00-10:50: "Matching Clinical Trials of Therapeutics & Regulatory Mandates" - moderated by Dr. Andrew Brack (ARPA-H). Grateful to Dr. Brack for assembling and moderating this important panel.
389 views · 0 likes
· 0 reposts · 1 replies
Open on X →
As public demand for healthy longevity grows and pharma expands into aging-related indications, it is essential to keep the FDA in the dialogue. We are honored that FDA representatives will participate in the 13th Aging Research and Drug Discovery Meeting (ARDD 2026). https://t.c
3.1K views · 22 likes
· 9 reposts · 4 replies
Open on X →
Against accounts of the same size
11 posts from the last 90 days, next to the 10K–100K follower range. reaches fewer people than peers of the same size.
Median views664this account924median for 10K–100K
Reach, %1.68%this account3.62%median for 10K–100K
Engagement, %1.59%this account1.52%median for 10K–100K
| Metric | This account | Median for 10K–100K | Ratio |
|---|---|---|---|
| Median views per post | 664 | 924 | 0.72× |
| Reach (views ÷ followers) | 1.68% | 3.62% | 0.47× |
| Engagement rate | 1.59% | 1.52% | 1.05× |
Others in this range → Compare with another account → How these benchmarks are built →
Growth & engagement
How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.
Views per post
3.1K25 Aug
389
664
4.2K2 Sep
25
118
643 Sep
31
1.2K
2.4K
1.2K
Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.
Engagement rate per post
1.12%25 Aug
0.26%
0.15%
2.76%2 Sep
0.00%
2.54%
4.69%3 Sep
0.00%
1.95%
3.57%
1.59%
Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.
What the audience does
Likes60.0%204 in total
Reposts15.3%52 in total
Replies7.9%27 in total
Quotes1.2%4 in total
Bookmarks15.6%53 in total
Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.
The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.
Similar accounts
Dylan Llewellyn
@Djllewellyn
78.8K followers
· 2.5K posts
Timothy “EDGYTIM” OHalloran
@EDGYTIM
78.8K followers
· 152.5K posts
Keblack
@KeblackOfficiel
78.8K followers
· 3.5K posts
TéléStar ✓
@Telestarmag
78.8K followers
· 117.7K posts
Motociclismo España ✓
@motociclismo_es
78.8K followers
· 55.8K posts
Transport Scotland
@transcotland
78.8K followers
· 22.8K posts
Joyce Hawkins
@mombreezy
78.8K followers
· 15.3K posts
Mercy Foodstuffs and Data vendor
@ademoye_mercy
78.8K followers
· 109.9K posts
Frequently asked questions about @biogerontology
How many followers does @biogerontology have?
39 417 followers.
How many posts has @biogerontology published?
15 372 posts.
How do posts by @biogerontology perform?
Collected posts: 11. Views: 13 392. Likes: 204.